Loading...
Early indication of survival benefit from ERCC1 and RRM1 tailored chemotherapy in patients with advanced Non-Small Cell Lung Cancer (NSCLC). Evidence from an individual patient analysis
BACKGROUND: ERCC1 and RRM1 are molecular determinants that predict sensitivity or resistance to platinum agents and gemcitabine, respectively. Tailored therapy using these molecular determinants suggests patient benefit in a previously reported phase II trial. Here we report an individual patient an...
Na minha lista:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2011
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3270127/ https://ncbi.nlm.nih.gov/pubmed/22028294 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.26522 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|